Tetracycline |
| カタログ番号GC37769 |
テトラサイクリンは、経口活性を持つ広域抗生物質です。
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 60-54-8
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Tetracycline (TC) is a broad-spectrum antibiotic with oral activity. It is effective against a variety of bacteria, including gram-positive and gram-negative bacteria, chlamydia, mycoplasma, and Rickettsia. It is used in the study of infections and can induce gene expression in the corresponding system[1-4].
Tetracycline (6.25-250 μM) was dose-dependent on NO synthetase activity and nitrite formation in J774 cells[5].
Tetracycline treatment delays the onset and slows the progression of diabetes in human amylin/islet amyloid polypeptide (hA/hIAPP) transgenic mice. Chronic oral administration of tetracycline (0.03 mg/ml in drinking water) from weaning enhances glycemic control and extends lifespan in hemizygous mice [6]. In a dog model of acute ischemia, 4mg/kg tetracycline injected 30 min prior to the occlusion improved the functional recovery from stunning of myocardium caused by ischemia[7]. Tetracycline injection at single doses of 1.5, 10, and 20 mg/kg significantly protected mice from a lethal intraperitoneal injection of LPS[8].
References:
[1]. Platt BN, Jacobs CA, et,al. Tetracycline use in treating osteoarthritis: a systematic review. Inflamm Res. 2021 Mar;70(3):249-259. doi: 10.1007/s00011-021-01435-4. Epub 2021 Jan 29. PMID: 33512569.
[2]. Chopra I, Roberts M. Tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistance. Microbiol Mol Biol Rev. 2001 Jun;65(2):232-60 ; second page, table of contents. doi: 10.1128/MMBR.65.2.232-260.2001. PMID: 11381101; PMCID: PMC99026.
[3]. Roberts MC. Tetracycline therapy: update. Clin Infect Dis. 2003 Feb 15;36(4):462-7. doi: 10.1086/367622. Epub 2003 Jan 28. PMID: 12567304.
[4]. Aiba A, Nakao H. Conditional mutant mice using tetracycline-controlled gene expression system in the brain. Neurosci Res. 2007 Jun;58(2):113-7. doi: 10.1016/j.neures.2007.01.009. Epub 2007 Jan 20. PMID: 17316857.
[5]. D'Agostino P, Arcoleo F, et,al. Tetracycline inhibits the nitric oxide synthase activity induced by endotoxin in cultured murine macrophages. Eur J Pharmacol. 1998 Apr 10;346(2-3):283-90. doi: 10.1016/s0014-2999(98)00046-6. PMID: 9652371.
[6]. Aitken JF, Loomes KM, et,al. Tetracycline treatment retards the onset and slows the progression of diabetes in human amylin/islet amyloid polypeptide transgenic mice. Diabetes. 2010 Jan;59(1):161-71. doi: 10.2337/db09-0548. Epub 2009 Sep 30. PMID: 19794060; PMCID: PMC2797917.
[7]. Kagawa N, Senbonmatsu TA, et,al. Tetracycline protects myocardium against ischemic injury. Front Biosci. 2005 Jan 1;10:608-19. doi: 10.2741/1557. PMID: 15569603.
[8]. Milano S, Arcoleo F, et,al. Intraperitoneal injection of tetracyclines protects mice from lethal endotoxemia downregulating inducible nitric oxide synthase in various organs and cytokine and nitrate secretion in blood. Antimicrob Agents Chemother. 1997 Jan;41(1):117-21. doi: 10.1128/AAC.41.1.117. PMID: 8980766; PMCID: PMC163671.
Average Rating: 5 (Based on Reviews and 28 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *